Breadcrumb
- Home /
- Research /
- Researcher Profiles /
- Researchers /
- David Labbé, PhD
null David Labbé, PhD
Junior Scientist, RI-MUHC , Glen site
Cancer Research ProgramCentre for Translational Biology
Assistant Professor, Department of Surgery, Faculty of Medicine, McGill University
- 514-934-1934 ext. 76361
- david.labbe@mcgill.ca
Keywords
Prostate cancer • nutrition/diet • epigenetics • animal models • translational research
Research Focus
Systemic metabolic alterations associated with increased consumption of saturated fat and obesity are linked with increased risk of prostate cancer progression and mortality, but the molecular underpinnings of this association are poorly understood. My research program is aimed at understanding the combination of key tumour genetic alterations together with the host characteristics required for diet to alter prostate cancer progression. This will allow the identification of new therapeutic targets and the elaboration of novel therapeutic approaches devised to treat prostate cancer patients at risk of progression to an aggressive, lethal disease. More specifically, my research focuses on the mechanisms and therapeutic targets related to epigenetic alterations and uses murine and human cell lines, animal models (including genetically engineered mouse models) and human tissues.
Selected Publications
Click on
to see my current publications list
-
Labbé, DP.; Zadra, G.; Yang, M.; Reyes, JM.; Lin, CY.; Cacciatore, S.; Ebot, EM.; Creech, AL.; Giunchi, F.; Fiorentino, M.; Elfandy, H.; Syamala, S.; Karoly, ED.; Alshalalfa, M.; Erho, N.; Ross, A.; Schaeffer, EM.; Gibb, EA.; Takhar, M.; Den, RB.; Lehrer, J.; Karnes, RJ.; Freedland, SJ.; Davicioni, E.; Spratt, DE.; Ellis, L.; Jaffe, JD.; DʼAmico, AV.; Kantoff, PW.; Bradner, JE.; Mucci, LA.; Chavarro, JE.; Loda, M.; Brown, M. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program, Nature Communications, 10(1) (2019) 4358. PMID: 31554818.
-
Labbé, DP.; Brown, M. Transcriptional regulation in prostate cancer, Cold Spring Harbor Perspectives in Medicine, 8(11) (2018) a030437. PMID: 29530947.
-
Labbé, DP.; Sweeney, CJ.; Brown, M.; Galbo, P.; Rosario, S.; Wadosky, KM.; Ku, SY.; Sjöström, M.; Alshalalfa, M.; Erho, N.; Davicioni, E.; Karnes, RJ.; Schaeffer, EM.; Jenkins, RB.; Den, RB.; Ross, AE.; Bowden, M.; Huang, Y.; Gray, KP.; Feng, FY.; Spratt, DE.; Goodrich, DW.; Eng, KH.; Ellis, L. TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup, Clinical Cancer Research, 23(22) (2017) 7072-7083. PMID: 28899973.
-
Ku, S-Y.; Rosario, S.; Wang, Y.; Mu, P.; Seshari, M.; Goodrich, ZW.; Goodrich, MM.; Labbé, DP.; Gomez, EC.; Wang, J.; Long, HW.; Xu, B.; Brown, M.; Loda, M.; Sawyers, CL.; Ellis, L.; Goodrich, DW. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis and antiandrogen resistance, Science, 355(6320) (2017) 78-83. PMID: 28059767.
-
Labbé, DP.; Uetani, N.; Vinette, V.; Lessard, L.; Aubry, I.; Migon, E.; Sirois, J.; Haigh, JJ.; Bégin, LR.; Trotman, LC.; Paquet, M.; Tremblay, ML. PTP1B deficiency enables the ability of a high fat diet to drive the invasive character of PTEN-deficient prostate cancers, Cancer Research (Priority Report), 76(11) (2016) 3130-3135. PMID: 27020859.